Atrinsic Inc. (NASDAQ:PTIX) Sees Significant Decrease in Short Interest

Atrinsic Inc. (NASDAQ:PTIX) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 50,768 shares, a decrease of 17.7% from the December 15th total of 61,712 shares. Based on an average trading volume of 53,322 shares, the days-to-cover ratio is presently 1.0 days. Approximately 2.9% of the company’s shares are sold short. Approximately 2.9% of the company’s shares are sold short. Based on an average trading volume of 53,322 shares, the days-to-cover ratio is presently 1.0 days.

Atrinsic Stock Performance

Shares of PTIX opened at $0.59 on Monday. The company’s 50-day simple moving average is $1.47 and its 200-day simple moving average is $2.63. Atrinsic has a 1 year low of $0.26 and a 1 year high of $14.28. The stock has a market capitalization of $1.14 million, a PE ratio of -0.07 and a beta of 0.51.

Atrinsic (NASDAQ:PTIX) last announced its quarterly earnings data on Wednesday, November 26th. The company reported ($0.47) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Atrinsic in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

About Atrinsic

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.